Tradestie Institutional Equity Comparison Engine

NTLA vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Options & Structure while NTLA counters with relative strength in Momentum & Technical. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
NTLA N/M vs CRSP 23.4x Fwd P/E
Growth & Margin Winner CRSP
Op Margin -826.0% vs -2058.6% ยท YoY -48.0% vs +1325.1%
Momentum & Technical Winner NTLA
1Y +15.3% vs -20.5% ยท 52W Pos 20% vs 1%
Options & Structure Winner CRSP
BREAKDOWN (78th %ile IV) vs BREAKDOWN (52nd %ile IV)
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
1M Return -12.43%
1Y Return +15.34%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NTLA +15.34% CRSP -20.54% Spread: +35.88 pp (NTLA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NTLA Revenue CRSP Revenue NTLA Op. Margin CRSP Op. Margin Margin Edge
FY2018 $30M $0M -298.6% -5087.8% NTLA
FY2019 $40M $290M -246.8% 16.1% CRSP
FY2020 $60M $0M -235.5% -49295.5% NTLA
FY2021 $30M $910M -810.4% 40.8% CRSP
FY2022 $50M $0M -879.0% -56190.4% NTLA
FY2023 $40M $370M -1420.5% -60.0% CRSP
FY2024 $60M $40M -923.1% -1250.4% NTLA
FY2025 $70M $0M -651.7% -18933.6% NTLA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NTLA (3) vs CRSP (6)
Institutional Metric NTLA CRSP Criterion Row Winner
Market Capitalization Scale $1.5B $4.1B Larger Scale CRSP
Trailing P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY) Growth -48.0% +1325.1% Higher Growth CRSP
Operating Margin (TTM) Profitability -826.0% -2058.6% Higher Margin NTLA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.6% -25.6% Higher ROE CRSP
52-Week Range Position Momentum 20% ($8โ€“$18) 1% ($40โ€“$63) Stronger Trend NTLA
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite NTLA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NTLA vs CRSP Buy Guide
NTLA BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 78th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live NTLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NTLA nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.